miRNA regulation of gene expression: a predictive bioinformatics analysis in the postnatally developing monkey hippocampus

Regulation of gene expression in the postnatally developing hippocampus might contribute to the emergence of selective memory function. However, the mechanisms that underlie the co-regulation of expression of hundreds of genes in different cell types at specific ages in distinct hippocampal regions have yet to be elucidated. By performing genome-wide microarray analyses of gene expression in distinct regions of the monkey hippocampal formation during early postnatal development, we identified one particular group of genes exhibiting a down-regulation of expression, between birth and six months of age in CA1 and after one year of age in CA3, to reach expression levels observed at 6–12 years of age. Bioinformatics analyses using NCBI, miRBase, TargetScan, microRNA.org and Affymetrix tools identified a number of miRNAs capable of regulating the expression of these genes simultaneously in different cell types, i.e., in neurons, astrocytes and oligodendrocytes. Interestingly, sixty-five percent of these miRNAs are conserved across species, from rodents to humans; whereas thirty-five percent are specific to primates, including humans. In addition, we found that some genes exhibiting greater down-regulation of their expression were the predicted targets of a greater number of these miRNAs. In sum, miRNAs may play a fundamental role in the co-regulation of gene expression in different cell types. This mechanism is partially conserved across species, and may thus contribute to the similarity of basic hippocampal characteristics across mammals. This mechanism also exhibits a phylogenetic diversity that may contribute to more subtle species differences in hippocampal structure and function observed at the cellular level.

ECP09-03 - Information technologies in psychiatry

Even if technology and information are omnipresent, they rarely meet harmoniously. Either the lack of sufficient means prevents good information to reach its target or the technology is too complex to integrate flawlessly in the daily workflow.

The use and misuse of information technologies (internet, email, e-learning, social networks) has recently significantly increased among psychiatrists and patients and the changes in behavior of communication and seeking informations are real challenges.

Using the European Federation of Psychiatric Trainees network, the self-questionnaires concerning the usage of information technologies and the local patients-therapists communication were distributed among psychiatric trainees of 31 European countries.

A review of the results of this study, as well as recommendations about netiquette and useful websites for psychiatrists and scientists will be presented in detail.

ECP09-02 - Psychiatry training in europe: Implementation and evaluation of training programs

Training schemes in psychiatry are developed and evaluated by national education policy makers in the majority of European countries. However, the requirements that a training program in psychiatry should meet are also defined on the European level in a form of recommendations by the Board of Psychiatry - European Union of Medical Specialists (UEMS).

Recently, the European Federation of Psychiatric Trainees (EFPT) which represent trainees from more then 30 European countries, reported data pertaining to the structure of training programs and to the evaluation of training programs in 30 European countries. Whereas in the majority of European countries the structure of training programs and methods of assessment of trainees' competencies are partially compatible with one another and with the existing recommendations at the European level, the quality assurance of training programs varies significantly among countries. Regular evaluations of training programs and mentors, however, contribute to the proper implementation of training programs and help that the theoretical training principles are followed through in practice. As quality assurance of training schemes is an important mechanism how to improve the delivery of training programs, it should gain more focus by responsible authorities who structure the psychiatric training on the national and international European level.

ECP09-01 - European federation of psychiatric trainees: Visions for the future

There are significant differences in psychiatric training across Europe. In the light of the current direction of Europe (without borders with free movement of workforce) it is inevitable to harmonize at least basic standards of psychiatric education across Europe. Ideally by working in partnership with relevant national and international bodies (European Union of Medical Specialists, Board of Psychiatry - UEMS, European Psychiatric Association - EPA and European Federation of Psychiatric Trainees - EFPT). A qualitative data analysis on the most important challenges of psychiatric trainees across Europe, carried out by the EFPT in 2009, revealed several interesting findings which might be of interest not only for trainees, but for all involved in the process of psychiatric education. As the most important issue trainees reported the imperfect structure of the training programs and problems with implementation of new ones. That is why new training programs based on a competency based framework are being developed lately in number of countries (e.g. United Kingdom, Ireland, Netherlands). However, not only the structure of the training and its implementation remains an issue, trainees are concerned also with topics related to working conditions, insufficient training opportunities, lack of supervision, funding and availability of psychotherapy courses, etc. Based on these findings EFPT will undertake specific actions which in cooperation with other organizations shall lead in the future to better postgraduate training opportunities in Europe.

Synthesis and application of a N-1' fluorescent biotinyl derivative inducing the specific carboxy-terminal dual labeling of a novel RhoB-selective scFv

The fluorescent site-specific labeling of protein would provide a new, easy-to-use alternative to biochemical and immunochemical methods. We used an intein-mediated strategy for covalent labeling of the carboxy-terminal amino acid of a RhoB-selective scFv previously isolated from a phage display library (a human synthetic V(H) + V(L) scFv phage library). The scFv fused to the Mxe intein was produced in E. coli and purified and was then labeled with a newly synthesized fluorescent biotinyl cysteine derivative capable of inducing scFv-Mxe intein splicing. In this study, we investigated the splicing and labeling properties of various amino acids in the hinge domain between scFv and Mxe under thiol activation. In this dual labeling system, the fluorescein is used for antibody detection and biotin is used for purification, resulting in a high specific activity for fluorescence. We then checked that the purified biotinylated fluorescent scFv retained its selectivity for RhoB without modification of its affinity.

High duty factor plasma generator for CERN's Superconducting Proton Linac

CERN's Linac4 is a 160 MeV linear accelerator currently under construction. It will inject negatively charged hydrogen ions into CERN's PS-Booster. Its ion source is a noncesiated rf driven H(-) volume source directly inspired from the one of DESY and is aimed to deliver pulses of 80 mA of H(-) during 0.4 ms at a 2 Hz repetition rate. The Superconducting Proton Linac (SPL) project is part of the luminosity upgrade of the Large Hadron Collider. It consists of an extension of Linac4 up to 5 GeV and is foreseen to deliver protons to a future 50 GeV synchrotron (PS2). For the SPL high power option (HP-SPL), the ion source would deliver pulses of 80 mA of H(-) during 1.2 ms and operate at a 50 Hz repetition rate. This significant upgrade motivates the design of the new water cooled plasma generator presented in this paper. Its engineering is based on the results of a finite element thermal study of the Linac4 H(-) plasma generator that identified critical components and thermal barriers. A cooling system is proposed which achieves the required heat dissipation and maintains the original functionality. Materials with higher thermal conductivity are selected and, wherever possible, thermal barriers resulting from low pressure contacts are removed by brazing metals on insulators. The AlN plasma chamber cooling circuit is inspired from the approach chosen for the cesiated high duty factor rf H(-) source operating at SNS.

Correlation between RhoB and Estrogen Receptor α (ERα) Expressions: From Experimental Data to Human Breast Tumors

Introduction: Hormonotherapy (HT) of breast cancers (BC) is strongly limitated by the resistances. Because Rho proteins are key elements in the cross-talks between ERα and growth factors signaling, they may be involved in the response to HT. RhoB could play a negative role in oncogenesis but there is no valid data regarding RhoB expression in BC. Experimental results: Our data suggest that RhoB participates in the balance of expression of ERα. The inhibition of the expression of RhoB using two sequences of interfering RNA in hormonodependent cell lines (MCF-7, T47D, ZR75) and in anti-estrogen resistant cell lines (LCC2, LCC9), decreases the expression of ERα both at the protein and mRNA levels. Moreover, in Mouse Embryonic Fibroblasts and uteri collected from RhoB knock-out mice, a dramatic decrease of ERα expression is observed. We therefore investigated the expression level of RhoB and ERα in BC tumors. Patients and methods: A tissue microarray (TMA) was constructed from a cohort of 113 patients (pts) enrolled in a randomized trial for adjuvant tamoxifen (median follow-up: 249.9 months). RhoB, ERα, and PR expressions were measured by immunochemistry. Cut-off used for ERα and PR + was 10% of stained cells. The expression of RhoB was calculated with the IRS score. Correlation of RhoB expression score with clinically diagnostic and prognostic variables was assessed using Man Whitney and Spearman's rank tests. Univariate survival analysis was performed for disease free survival (DFS) by applying the log-rank test to RhoB expression levels stratified by median value. TMA results: 65 (58.6%) were grade I-II; 74(66.1%) were ERα+ and 59(52.7%) PR+; 23 (22.1%) presented lymphovascular (LV) invasion. 39 pts (34.8%) had lymph nodes (LN) +. Pts under tamoxifen (n=62) had a less favorable pathological profile regarding + LN (p=0.0039), pathological tumour size (p=0.0486) and number of mitoses (p=0.0556). Age, ERα/PR status, histological grade or type and LV invasion status were similar in the two groups. We found less RhoB IRS expression in pts with tumor grade III (median 8 [1;12]) than in grade I-II (median 9 [3;12], p=0.0142). RhoB IRS expression was much higher in ERa + tumors (median:10.5 [3;12]) than in ERa negative tumors (median=8 [1;12], p=0.0023). RhoB IRS score was not correlated with the presence or not of LV invasion (p=0.26), neither with the presence of LN invasion (p= 0.74). Furthermore, RhoB expression is i) strongly correlated with the % of expression of ERα (Spearman'sρ=0.3659; p = 0.001) and PR (Spearman's ρ=0.2544 ; p=0.0076) ii) inversely correlated with histologic size (Spearman's ρ= -0.2344 ; p = 0.0166) and with number of mitose (Spearman's ρ=-0.2009 ; p=0.0362). The DFS of pts with ERα + tumors under tamoxifen or not was not affected by the level of RhoB expression. Conclusion: The analysis of 113 human breast tumors allowed to confirm experimental results, demonstrating that RhoB expression is strongly correlated with ERα expression. The role of RhoB as a potential suppressor gene of tumours in BC and its role in the response to HT have then to be investigated further.

Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5146.

Sideroblastic changes of the bone marrow can be predicted by the erythrogram of peripheral blood

The diagnosis of sideroblastic anemia is based on bone marrow aspiration, and the detection of ring sideroblasts (RS) in iron staining. The finding of laboratory parameters to approach this diagnosis still remains a great challenge. In this study, we analyzed the value of a specific erythrogram pattern from peripheral blood, produced by the ADVIA120 cell counter, to predict sideroblastic changes in the bone marrow. In a two step-design study, we first showed that 32/38 consecutive patients reporting > or =15% RS had such a pattern in the erythrogram. In the second step, we prospectively identified over a period of 32 months 21 patients with this typical erythrogram; 20/21 had > or =15% RS in the bone marrow. Hence, by this validation, we confirm that the erythrogram is highly predictive of RS in the bone marrow. The interpretation of the erythrogram should become daily practice in hematology to improve the efficacy to detect sideroblastic changes.

Preclinical study of an ex vivo gene therapy protocol for hepatocarcinoma

Preclinical studies in several animal models as well as clinical trials have shown a reduction in tumor growth following immunotherapy with interleukin-12 (IL-12). This cytokine is appropriate to test in therapeutic clinical trials to treat hepatocarcinoma (HC), a pathology often associated with hepatitis B or C-induced cirrhosis. The local delivery into the liver would be achieved through ex vivo gene transfer using retroviral (rv) vectors in autologous fibroblast carriers. In support of this clinical trial, a rv vector has been constructed to express coordinately both chains p35 and p40 of human IL-12. Here, we have tested good manufacturing practices (GMP) clinical lots of viral vectors derived from the transfected packaging cell line, PG13rvIL-12. We have also devised methods to facilitate the isolation of fibroblasts from freshly harvested skin specimens, enhance their outgrowth in large-scale cultures and assay IL-12 production following transduction, without any selection and irradiation. Twenty-four human skin specimens were processed to obtain fibroblast suspensions that were typically maintained for up to 8 or 12 passages. The mean +/-s.d. overall time for obtaining the required number of transduced cells for the highest IL-12 need was 40 days. The procedure, in accordance with the French medical agency for gene therapy clinical trials, is now ready to begin a clinical trial.